interleukin-1 receptor-associated kinase 4

Nomenclature: interleukin-1 receptor-associated kinase 4

Abbreviated Name: IRAK4

Family: Interleukin-1 receptor-associated kinase (IRAK) family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 460 12q12 IRAK4 interleukin-1 receptor-associated kinase 4
Mouse - 459 15 F1 Irak4 interleukin-1 receptor-associated kinase 4
Rat - 461 7 q35 Irak4 interleukin-1 receptor-associated kinase 4
Previous and Unofficial Names
Renal carcinoma antigen NY-REN-64
Irak4_predicted
LOC300177
IRAK-4
Database Links
BRENDA
Ensembl Gene
Entrez Gene
ExplorEnz
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG BRITE Hierarchy
KEGG Gene
OMIM
Orphanet Gene
PhosphoSitePlus
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene
UniProtKB
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of IRAK-4
PDB Id:  2NRU
Resolution:  2.0Å
Species:  Human
References:  5
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of IRAK4 kinase domain complexed with AMPPNP
PDB Id:  2OID
Ligand:  AMP-PNP
Resolution:  2.3Å
Species:  Human
References:  4
Enzyme Reaction
EC Number: 2.7.11.1
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 2,6

Key to terms and symbols Click column headers to sort
Target used in screen: IRAK4
Ligand Sp. Type Action Affinity Units
staurosporine Hs Inhibitor Inhibition 8.77 pKd
lestaurtinib Hs Inhibitor Inhibition 8.77 pKd
sunitinib Hs Inhibitor Inhibition 7.18 pKd
vandetanib Hs Inhibitor Inhibition 7.12 pKd
TAE 684 Hs Inhibitor Inhibition 7.11 pKd
SU-14813 Hs Inhibitor Inhibition 7.09 pKd
dovitinib Hs Inhibitor Inhibition 6.89 pKd
R406 Hs Inhibitor Inhibition 6.85 pKd
bosutinib Hs Inhibitor Inhibition 6.44 pKd
gefitinib Hs Inhibitor Inhibition 6.27 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx


Reference: 1,3

Key to terms and symbols Click column headers to sort
Target used in screen: IRAK4/IRAK4
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
K-252a Hs Inhibitor Inhibition 1.0 -2.0 0.0
Syk inhibitor Hs Inhibitor Inhibition 3.0 0.0 -1.0
staurosporine Hs Inhibitor Inhibition 3.5 1.0 0.5
JAK3 inhibitor VI Hs Inhibitor Inhibition 8.3 3.0 1.0
SB 218078 Hs Inhibitor Inhibition 14.0 38.0 18.0
Cdk1/2 inhibitor III Hs Inhibitor Inhibition 19.6 8.0 0.0
SU11652 Hs Inhibitor Inhibition 22.7 22.0 7.0
IRAK-1/4 inhibitor Hs Inhibitor Inhibition 22.8 13.0 15.0
sunitinib Hs Inhibitor Inhibition 27.4
dovitinib Hs Inhibitor Inhibition 31.8
Displaying the top 10 most potent ligands  View all ligands in screen »
Clinically-Relevant Mutations and Pathophysiology
Disease:  IRAK4 deficiency
OMIM:  607676
Orphanet:  70592
References: 
Mutations not determined
Disease:  Invasive pneumococcal disease, recurrent isolated, 1
OMIM:  610799
References: 
Mutations not determined

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol.29 (11): 1039-45. [PMID:22037377]

2. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol.29 (11): 1046-51. [PMID:22037378]

3. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J.451 (2): 313-28. [PMID:23398362]

4. Kuglstatter A, VillaseƱor AG, Shaw D, Lee SW, Tsing S, Niu L, Song KW, Barnett JW, Browner MF. (2007) Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. J. Immunol.178 (5): 2641-5. [PMID:17312103]

5. Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP. (2006) Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure14 (12): 1835-44. [PMID:17161373]

6. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol.17 (11): 1241-9. [PMID:21095574]

How to cite this page

Interleukin-1 receptor-associated kinase (IRAK) family: interleukin-1 receptor-associated kinase 4. Last modified on 25/03/2014. Accessed on 01/11/2014. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045.